The presentation will provide an overview of the U.S.Food and Drug Administration (FDA) approval process for follow-on biologics under the new U.S.healthcare law; the doctrine of Patent Misuse in the context of extended royalty term; transactional strategies for further technologies and protecting future fights; and the landscape of recent transactions involving biosimilars.